In the press

Matthew Read comments on SCP deal for Saba exit in Investment Week

Biotech trusts top performance charts in February

Matthew Read comments on SCP’s tender offer with Saba exit and standstill deal in Linus Uhlig’s article:

“Saba gets a route to exit at close to NAV, while remaining shareholders avoid the prolonged uncertainty and distraction of an activist battle. The three-year standstill agreement removes the immediate threat of further agitation, giving the board and manager space to prove the merits of the strategy.”

Read the article here